Publication: Treatment of Epstein-Barr virus lymphoproliferative disease after hematopoietic stem-cell transplantation with hydroxyurea and cytotoxic T-cell lymphocytes
Issued Date
2004-09-15
Resource Type
ISSN
00411337
Other identifier(s)
2-s2.0-4544344289
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Transplantation. Vol.78, No.5 (2004), 755-757
Suggested Citation
Samart Pakakasama, Gretchen M. Eames, Michael C. Morriss, M. Helen Huls, Cliona M. Rooney, Helen E. Heslop, Robert A. Krance Treatment of Epstein-Barr virus lymphoproliferative disease after hematopoietic stem-cell transplantation with hydroxyurea and cytotoxic T-cell lymphocytes. Transplantation. Vol.78, No.5 (2004), 755-757. doi:10.1097/01.TP.0000129813.54517.25 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/21539
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Treatment of Epstein-Barr virus lymphoproliferative disease after hematopoietic stem-cell transplantation with hydroxyurea and cytotoxic T-cell lymphocytes
Abstract
Epstein-Barr virus (EBV) lymphoproliferative disease (LPD) is a potentially fatal complication that may follow allogeneic hematopoietic stem-cell transplantation (HSCT). In this article, the authors report a 2-year-old girl with Hurler's syndrome who developed multiple central nervous system (CNS) EBV LPD lesions 1 year after unrelated donor HSCT. Before this CNS occurrence, the patient had a complete response to rituximab treatment for EBV LPD of the spleen and lymph nodes; however, treatment of the CNS disease with rituximab proved ineffective. Because of reported favorable response of primary CNS EBV LPD in two human immunodeficiency virus-positive patients, the authors treated this patient with low-dose oral hydroxyurea. The patient improved clinically, with a decrease in size of multiple EBV LPD brain lesions. Subsequently, the patient received EBV-specific cytotoxic T-cell lymphocytes and remains well. The benefit and limited toxicity of hydroxyurea therapy merit its further consideration as treatment for EBV LPD.